Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COAG NASDAQ:IMTX NASDAQ:INBX NASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$28.75-1.4%$0.00$23.00▼$36.61$1.34BN/A263,077 shs134,975 shsIMTXImmatics$10.02+1.1%$10.66$5.05▼$12.41$1.33B1.3494,189 shs675,906 shsINBXInhibrx Biosciences$95.10+2.4%$104.34$13.97▼$155.29$1.36B3.31304,004 shs316,208 shsSLNSilence Therapeutics$9.16+26.0%$6.94$4.19▼$9.46$343.40M1.48246,199 shs2.23 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-8.16%+14.27%+12.59%+2,914,999,900.00%+2,914,999,900.00%IMTXImmatics+1.53%+9.24%-14.54%+1.95%+83.21%INBXInhibrx Biosciences-0.42%-0.21%-8.30%+39.80%+538.12%SLNSilence Therapeutics-3.45%+8.35%+17.26%+32.91%+26.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$28.75-1.4%$0.00$23.00▼$36.61$1.34BN/A263,077 shs134,975 shsIMTXImmatics$10.02+1.1%$10.66$5.05▼$12.41$1.33B1.3494,189 shs675,906 shsINBXInhibrx Biosciences$95.10+2.4%$104.34$13.97▼$155.29$1.36B3.31304,004 shs316,208 shsSLNSilence Therapeutics$9.16+26.0%$6.94$4.19▼$9.46$343.40M1.48246,199 shs2.23 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics-8.16%+14.27%+12.59%+2,914,999,900.00%+2,914,999,900.00%IMTXImmatics+1.53%+9.24%-14.54%+1.95%+83.21%INBXInhibrx Biosciences-0.42%-0.21%-8.30%+39.80%+538.12%SLNSilence Therapeutics-3.45%+8.35%+17.26%+32.91%+26.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOAGHemab Therapeutics 2.83Moderate Buy$41.4044.00% UpsideIMTXImmatics 2.63Moderate Buy$20.80107.58% UpsideINBXInhibrx Biosciences 2.33Hold$150.0057.73% UpsideSLNSilence Therapeutics 2.83Moderate Buy$55.00500.44% UpsideCurrent Analyst Ratings BreakdownLatest SLN, COAG, INBX, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SLNSilence Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight6/17/2026SLNSilence Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.006/17/2026COAGHemab Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/17/2026COAGHemab Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/16/2026INBXInhibrx Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/9/2026IMTXImmatics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AIMTXImmatics$54.60M24.60N/AN/A$4.09 per share2.45INBXInhibrx Biosciences$1.30M1,073.17N/AN/A$0.55 per share172.91SLNSilence Therapeutics$560K772.71N/AN/A$1.32 per share6.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AIMTXImmatics-$222.26M-$1.99N/AN/AN/A-572.35%-47.36%-39.35%8/12/2026 (Estimated)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)SLNSilence Therapeutics-$88.61M-$1.59N/AN/AN/A-8,943.86%-105.34%-52.79%8/6/2026 (Estimated)Latest SLN, COAG, INBX, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/12/2026Q1 2026IMTXImmatics-$0.42-$0.50-$0.08-$0.50$9.79 million$8.81 million5/8/2026Q1 2026SLNSilence Therapeutics-$0.1850-$0.32-$0.1350-$0.33$1.26 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOAGHemab TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOAGHemab TherapeuticsN/AN/AN/AIMTXImmaticsN/A8.788.78INBXInhibrx Biosciences12.586.466.46SLNSilence TherapeuticsN/A9.839.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOAGHemab TherapeuticsN/AIMTXImmatics64.41%INBXInhibrx Biosciences82.46%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipCOAGHemab TherapeuticsN/AIMTXImmatics3.30%INBXInhibrx Biosciences18.26%SLNSilence Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOAGHemab Therapeutics7246.71 millionN/AN/AIMTXImmatics260134.07 million129.65 millionOptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionableSLNSilence Therapeutics10047.24 million45.82 millionNot OptionableSLN, COAG, INBX, and IMTX HeadlinesRecent News About These CompaniesSilence Therapeutics (NASDAQ:SLN) vs. Chugai Pharmaceutical (OTCMKTS:CHGCY) Head-To-Head ComparisonJune 24 at 2:08 AM | americanbankingnews.comSilence: 'Buy' Zerlasiran Program Shift And Divesiran Results August 2026June 12, 2026 | seekingalpha.comSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraJune 11, 2026 | businesswire.comSilence Therapeutics (SLN) Receives a Buy from H.C. WainwrightMay 27, 2026 | theglobeandmail.comSilence Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 27, 2026 | businesswire.comSilence Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLNMay 18, 2026 | benzinga.comSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor ConferenceMay 13, 2026 | pharmiweb.comPSilence Therapeutics highlights recent business achievements and reports first quarter 2026 financial resultsMay 7, 2026 | msn.comSilence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?April 16, 2026 | zacks.comSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | finance.yahoo.comWall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?March 5, 2026 | zacks.comSilence Therapeutics CEO Craig Tooman to end employmentDecember 15, 2025 | msn.comSilence Therapeutics Announces Leadership ChangesDecember 15, 2025 | businesswire.comSilence Therapeutics: Divesiran Targets High-Burden PVNovember 18, 2025 | seekingalpha.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | msn.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | businesswire.comIs Silence Therapeutics (NASDAQ:SLN) In A Good Position To Deliver On Growth Plans?October 17, 2025 | finance.yahoo.comSilence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comSilence Therapeutics to Participate in September Investor ConferencesSeptember 2, 2025 | businesswire.comSilence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLN, COAG, INBX, and IMTX Company DescriptionsHemab Therapeutics NASDAQ:COAG$28.75 -0.40 (-1.37%) As of 04:00 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Immatics NASDAQ:IMTX$10.02 +0.11 (+1.11%) Closing price 04:00 PM EasternExtended Trading$10.02 0.00 (0.00%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Inhibrx Biosciences NASDAQ:INBX$95.10 +2.19 (+2.36%) Closing price 03:59 PM EasternExtended Trading$95.13 +0.03 (+0.03%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Silence Therapeutics NASDAQ:SLN$9.16 +1.89 (+26.00%) Closing price 04:00 PM EasternExtended Trading$9.20 +0.04 (+0.46%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
